Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday ... PR Newswire (press release) In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian, colorectal, lung and brain cancers ... |
